ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Consensus Rating of “Moderate Buy” from Analysts

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has received an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, Marketbeat reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $103.00.

ANIP has been the topic of a number of recent analyst reports. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, September 9th. They set an “outperform” rating and a $104.00 price target on the stock. Guggenheim decreased their price target on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Wall Street Zen lowered ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, August 11th. Finally, Canaccord Genuity Group cut their price objective on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a research report on Monday, August 10th.

Insider Activity at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, Director Jeanne Thoma sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Friday, September 11th. The stock was sold at an average price of $71.53, for a total transaction of $71,530.00. Following the completion of the sale, the director directly owned 26,762 shares of the company’s stock, valued at $1,914,285.86. The trade was a 3.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $77.00, for a total value of $243,474.00. Following the transaction, the senior vice president owned 75,534 shares in the company, valued at approximately $5,816,118. This represents a 4.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 28,325 shares of company stock worth $2,177,695 over the last three months. Corporate insiders own 8.10% of the company’s stock.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in shares of ANI Pharmaceuticals by 1.5% during the 1st quarter. The Manufacturers Life Insurance Company now owns 9,577 shares of the specialty pharmaceutical company’s stock valued at $736,000 after acquiring an additional 143 shares during the last quarter. Oregon Public Employees Retirement Fund boosted its position in shares of ANI Pharmaceuticals by 5.1% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,086 shares of the specialty pharmaceutical company’s stock worth $323,000 after purchasing an additional 200 shares during the period. Hantz Financial Services Inc. boosted its position in shares of ANI Pharmaceuticals by 70.3% during the fourth quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 249 shares during the period. ProShare Advisors LLC boosted its holdings in ANI Pharmaceuticals by 8.0% during the 4th quarter. ProShare Advisors LLC now owns 4,520 shares of the specialty pharmaceutical company’s stock valued at $357,000 after acquiring an additional 336 shares during the period. Finally, New York State Teachers Retirement System grew its holdings in shares of ANI Pharmaceuticals by 1.6% in the first quarter. New York State Teachers Retirement System now owns 23,268 shares of the specialty pharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 356 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Trading Up 2.4%

NASDAQ:ANIP opened at $75.39 on Friday. The business has a fifty day moving average price of $76.30 and a 200-day moving average price of $78.12. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. ANI Pharmaceuticals has a one year low of $69.58 and a one year high of $98.55. The firm has a market capitalization of $1.73 billion, a price-to-earnings ratio of 16.25 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million for the quarter, compared to analysts’ expectations of $260.13 million. During the same period in the previous year, the firm earned $1.80 EPS. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts forecast that ANI Pharmaceuticals will post 7.83 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.

ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.